Patent ID: 11944641
Assignee: LPOXY THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 0:
1. A method for the treatment of inflammatory bowel disease (IBD), the method comprising:
oxygenating the gastrointestinal tract of a subject by administering to the gastrointestinal tract a formulation comprising:
an agent, a catalyst, a first controlled release coating encasing the agent, a second controlled release coating encasing the catalyst and the encased agent, a porous membrane that encapsulates the catalyst and the encased agent, and an enteric coating surrounding the oral formulation,
wherein the agent comprises sodium percarbonate or carbamide peroxide,
wherein the catalyst comprises catalase,
wherein the catalase controls the rate of conversion of the agent to oxygen,
wherein the porous membrane comprises at least two or more layers made of one or more of: cellulose propionates, cellulose acetate butyrates, cellulose acetate acetoacetate, cellulose chloroacetate, cellulose acetate furoate, dimethoxyethyl cellulose acetate with a functional pore size that prevents a majority of the catalyst from diffusing across the membrane,

wherein the functional pore size is smaller than an actual pore size,
wherein the pore size is sufficient to allow water to diffuse across any portion of the membrane to contact the agent and to allow oxygen to diffuse across any portion of the membrane into an intestine of the subject,
wherein when within the gastrointestinal tract of the subject, the catalase acts on the agent to generate a concentration of 2-5% oxygen in at least a portion of the gastrointestinal tract for 24 hours or more, thereby treating the IBD, and
wherein the formulation is in a solid form as a pill or a capsule.